Diphtheria News and Research

RSS

Diphtheria is a disease caused by a bacterium, Corynebacterium diphtheriae, that usually affects the tonsils, throat, nose and/or skin. It is passed from person to person by droplet transmission, usually by breathing in diphtheria bacteria after an infected person has coughed or sneezed. Although diphtheria disease is rare in the U.S., it appears that C diphtheriae continues to circulate in areas of the country with previously endemic diphtheria. Diphtheria also occurs in many other parts of the world.

Booster vaccine that includes protection against pertussis shows promise

A new combination vaccine not yet on the market appears to provide a booster for immunity against tetanus, diphtheria, and pertussis for adolescents and adults and was found to have a similar overall safety profile when compared to the current licensed tetanus-diphtheria vaccine, according to a new study in JAMA.

3 Jun 2005

Fragile US vaccine system needs improvement

A comprehensive system of vaccine development in the U.S. resulted in a reduction of 87 to more than 99 percent in illness from ten vaccine-preventable diseases during the twentieth century. These dramatic successes should not be taken for granted, however, as the vaccine system now faces numerous challenges in manufacturing and development, according to a review article in the May/June issue of Health Affairs.

10 May 2005

Boostrix receives FDA approval as treatment for pertussis

GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).

3 May 2005

Whooping cough makes a comeback

The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.

3 May 2005

Protection against 12 different communicable diseases available for infants and toddlers

In recognition of National Infant Immunization Week (April 24, 2005 through April 30, 2005), the Nassau County Department of Health urges all parents to ensure that their infants and toddlers are fully protected from the following vaccine preventable diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, measles, mumps, rubella, hepatitis B, haemophilus influenza (meningitis), varicella (chickenpox), pneumococcal disease and influenza.

12 Apr 2005

Vaccine prevents deadly pneumonia in African children

Global health leaders today presented new research showing that vaccinating infants against Streptococcus pneumoniae -- a bacterium that causes deadly pneumonia, meningitis and sepsis -- could substantially reduce death and serious illness among children in the developing world. If used widely, a pneumococcal conjugate vaccine could prevent hundreds of thousands of child deaths each year.

28 Mar 2005

Vaccine against pneumonia and invasive pneumococcal disease shows promise

A vaccine against pneumonia and invasive pneumococcal disease, a severe form of bacterial infection, can substantially reduce hospital admissions and improve the survival of children in developing countries, concludes a trial published in this week’s issue of The Lancet.

28 Mar 2005

Vaccine for whooping cough in teens

The U.S. Food and Drug Administration (FDA) is recommending the development of a vaccine to prevent the occurrence of pertussis (Whooping Cough) in adolescents.

15 Mar 2005

U.S. children undervaccinated

Approximately one-third of U.S. children were undervaccinated for more than six months and one-fourth experienced delays in receiving many of the recommended vaccinations during their first 24 months of life, according to a study in the current issue of JAMA.

9 Mar 2005

VIRxSYS novel HIV gene therapy yields exciting results

VIRxSYS Corporation reports unexpected and unprecedented findings in its ongoing Phase I clinical trial of its VRX496 therapy in patients with HIV.

28 Feb 2005

New method of delivery of gene therapy may lead to safer treatment for cancer

The Lankenau Institute for Medical Research (LIMR) announced that in collaboration with the Massachusetts Institute of Technology (MIT) they have performed preclinical proof-of- principle studies showing how nanotechnology can be used to enhance gene therapy for cancer.

25 Jan 2005

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for protection against meningococcal disease in adolescents and adults aged 11-55 years.

17 Jan 2005

New technologies boost immunisation rates, safety

As global health leaders struggle to meet the United Nations goal of reducing mortality among the world's poorest children, vaccines are attracting more and more attention. The purchase of the vaccine is just the beginning, however, as the effectiveness of a vaccine is only as good as its delivery system.

6 Dec 2004